U.S. Cryogenic Biobanking Services Market - Industry Outlook & Forecast 2025-2030

List of Tables

The U.S. cryogenic biobanking services is expected to grow at a CAGR of 5.85% from 2024 to 2030.

MARKET TRENDS & DRIVERS

Expansion of Virtual Biobanking

The expansion of virtual biobanking is a game-changer in the U.S. cryogenic biobanking services market. By bridging the gap between physical sample storage and digital data accessibility, it unlocks new potential for collaboration, research efficiency, and personalized medicine. With continued advancements and supportive regulatory frameworks, virtual biobanking will play a pivotal role in shaping the future of biomedical science.

Growing Conservation of Cord Blood Stem Cells of Newborns

The growing conservation of cord blood stem cells represents a transformative trend in the U.S. cryogenic biobanking services market. With its potential to revolutionize treatments for a wide range of diseases and its role in advancing regenerative medicine, cord blood banking is driving innovation and creating new opportunities for biobanking providers. By embracing this trend and overcoming associated challenges, the market is set to make significant contributions to healthcare and scientific advancements in the years to come.

Advancements in Cryopreservation Technology

Advancements in cryopreservation technology are revolutionizing the U.S. cryogenic biobanking services market, offering unprecedented opportunities for biomedical research, personalized medicine, and regenerative therapies. By enhancing the quality and longevity of biological samples, these innovations are driving progress in healthcare and opening new avenues for discovery. One of the most significant advancements in cryopreservation technology is the development of vitrification. This method involves ultra-rapid cooling, which prevents the formation of ice crystals that can damage cells, tissues, and other biological materials.

Emergence of Personalized Biobanking

With the rise of personalized medicine, the demand for tailored therapies and treatments is higher than ever, and biobanks are uniquely positioned to support this transformation. By providing valuable insights into individual health profiles, personalized biobanks are unlocking new opportunities in drug development, disease prevention, and precision medicine. Moreover, with the rapid progress in genomic technologies such as next-generation sequencing (NGS), personalized biobanks have become essential in the study of genomics and precision medicine. The ability to sequence an individual's genome and analyze genetic predispositions, disease risks, and drug responses is unlocking unprecedented opportunities in targeted therapies.

Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases in the U.S. has significantly boosted the demand for cryogenic biobanking services. By providing essential resources for research, diagnostics, and therapeutics, biobanking serves as a cornerstone in addressing the chronic disease burden. As the healthcare landscape evolves, cryogenic biobanking is poised to remain a vital tool in advancing medical science, improving patient outcomes, and transforming the way chronic diseases are understood and treated.

Surge in Clinical Trials for New Drugs and Therapies

The surge in clinical trials for new drugs and therapies is undeniably a driving force in the U.S. cryogenic biobanking services market. As the demand for efficient sample storage and management continues to grow, cryogenic biobanking will remain at the forefront of medical research and innovation. By supporting the development of life-saving treatments and therapies, the biobanking market is not only fueling market growth but also contributing to the advancement of global healthcare.

Expansion of Genomics and Proteomics Research

The expansion of genomics and proteomics research is a driving force behind the growth of the United States cryogenic biobanking services market. By providing essential storage solutions for biological specimens, cryogenic biobanks are enabling groundbreaking discoveries in precision medicine, disease diagnostics, and therapeutic development. As these fields continue to evolve, the role of cryogenic biobanking will remain pivotal in advancing the frontiers of medical and biological research, ultimately transforming patient care and health outcomes.

Favorable Government and Private Funding

Favorable government and private funding have undeniably been key drivers of the U.S. cryogenic biobanking services market. By supporting infrastructure development, technological innovation, and collaborative research, these funding efforts have positioned the U.S. as a global leader in biobanking. Examples like the NIH's All of Us program and private sector partnerships highlight the profound impact of financial backing, paving the way for innovative breakthroughs and improved healthcare outcomes.

SEGMENTATION INSIGHTS

INSIGHTS BY SERVICE TYPE

The U.S. cryogenic biobanking services market by service type is segmented into biobanking & repository, validation/qualification, lab processing, and others. The biobanking and repository segment dominates the market, offering secure cryogenic storage solutions for biological samples, such as tissues, blood, and cell cultures. These services ensure the long-term preservation of biomaterials, supporting research, drug development, and clinical applications. Furthermore, the validation/qualification segment focuses on ensuring that biobanking systems and equipment meet regulatory and operational standards. It includes temperature validation, equipment qualification, and process monitoring, which are critical for maintaining sample integrity.

Lab processing services include sample preparation, aliquoting, nucleic acid extraction, and cryopreservation protocols. These services enhance the usability of stored samples for downstream applications in research and diagnostics. Moreover, others encompass ancillary services such as sample transportation, and custom biobank solutions, which support efficient operations in biobanking facilities.

Segmentation by Service Type

Biobanking & Repository
Validation/Qualification
Lab Processing
Others

INSIGHTS BY SAMPLE TYPE

The human samples sample type holds the largest share of the U.S. cryogenic biobanking services market in 2024, driven by the demand for human tissues, blood, DNA, and cell cultures in research, clinical trials, and drug development. Human samples are critical for precision medicine, epidemiology, and regenerative therapies. Blood and plasma are among the most commonly stored samples in cryogenic biobanks. These samples are critical for a wide range of applications, including disease diagnostics, biomarker discovery, and therapeutic monitoring.

Animal samples are primarily used in preclinical studies, veterinary research, and conservation biology. Cryogenic storage of animal tissues and cells enables advancements in toxicology, genomics, and ecosystem restoration. Furthermore, plant samples are crucial for agricultural research, genetic studies, and biodiversity conservation. Cryogenic storage of seeds, tissues, and plant cells ensures the preservation of genetic diversity and supports ecosystem sustainability.

Segmentation by Sample Type

Human Samples
Animal Samples
Plant Samples
Others

INSIGHTS BY APPLICATION

The U.S. cryogenic biobanking services market by application is segmented into drug discovery & development, regenerative medicine, epidemiology & population health, and conservation & ecosystem restoration. The drug discovery & development segment dominated the U.S. market share in 2024. Cryogenic biobanking supports pharmaceutical R&D by storing high-quality samples for target identification, biomarker validation, and clinical trials. It is integral to developing novel therapeutics and personalized medicine.

Regenerative medicine involves the preservation of stem cells, tissues, and organoids for regenerative therapies. Cryogenic biobanking plays a pivotal role in advancing cell-based treatments and organ transplantation research. Furthermore, biobanks store large-scale population samples, enabling epidemiological studies, disease surveillance, and public health interventions. These repositories support the analysis of disease trends and healthcare planning.

Segmentation by Application

Drug Discovery & Development
Regenerative Medicine
Epidemiology & Population Health
Conservation & Ecosystem Restoration

INSIGHTS BY OWNERSHIP

The U.S. cryogenic biobanking services market by ownership is segmented into universities, non-profit organizations, state/government agencies, and private organizations. The universities segment holds the largest U.S. market share. Universities manage biobanks for research and educational purposes, focusing on advancing scientific knowledge in genomics, precision medicine, and regenerative therapies. By integrating cryogenic biobanking services into their institutions, universities foster innovation while supporting academic and collaborative research efforts.

Furthermore, non-profit organizations focus on disease-specific research and population health. They manage biobanks that support public health studies, epidemiology, and translational research. Also, state/government agencies operate biobanks for public health, disease control, and conservation initiatives. These repositories ensure equitable access to resources for national healthcare and biodiversity goals. Private organizations cater to commercial sectors such as pharmaceuticals and biotechnology. They provide customized storage, processing, and validation services to support drug development and research.

Segmentation by Ownership

Universities
Non-profit Organizations
State/Government Agencies
Private Organizations

INSIGHTS BY END-USER

The pharma & biotech companies end-user holds the most prominent share of the U.S. cryogenic biobanking services market share. Pharma and biotech companies utilize biobanking services for R&D, clinical trials, and drug development. Cryogenic biobanks support the storage of biological samples, enabling innovation in therapeutics and diagnostics. Academic and research institutions leverage cryogenic biobanking for genomics, population health studies, and translational medicine. These biobanks drive scientific advancements and innovation. Furthermore, healthcare providers such as hospitals and healthcare facilities use biobanking services to store patient samples for diagnostic purposes, therapeutic applications, and personalized treatment planning. CROs & CDMOs utilize biobanking for preclinical studies, clinical trials, and biomanufacturing processes. Cryogenic biobanking supports their contract-based operations. Also, life sciences firms rely on cryogenic biobanking for biotechnology research, including the development of biosimilars, cell therapies, and molecular diagnostics. Other end-users include medical device companies, public health agencies, and donors/participants that use cryogenic biobanking for various specialized applications.

Segmentation by End-User

Pharma & Biotech Companies
Academic & Research Institutes
Healthcare Providers
CROs & CDMOs
Life Sciences Companies
Others

COMPETITIVE LANDSCAPE

The U.S. cryogenic biobanking services market is a dynamic and competitive sector, fueled by the rising demand for long-term preservation of biological specimens for research, clinical, and commercial purposes. The competitive landscape is characterized by the presence of established market leaders, emerging players, and niche service providers. Companies in this market compete based on factors such as technological innovation, service diversity, quality assurance, compliance with regulatory standards, and strategic partnerships. Furthermore, the United States cryogenic biobanking services market is dominated by several established players, including specialized service providers, contract biobanking companies, and academic and healthcare institutions offering cryogenic storage solutions.

Furthermore, to maintain their positions and attract new clients, companies in the U.S. cryogenic biobanking services market employ a variety of competitive strategies. For instance, companies are expanding their service portfolios to include additional offerings such as disaster recovery solutions, regulatory consulting, and data integration with laboratory information management systems (LIMS). Also, many firms prioritize flexibility in service offerings, such as custom biobanking solutions tailored to specific client requirements, to differentiate themselves in the market.

Company Profiles

Azenta Life Sciences
BioDock (Future Health Group)
BioKryo
BioRepository Resources (Tobin Scientific)
Biostorage
BocaBio
Brigham and Women's Hospital Division of Preventive Medicine
Cell Culture Company
Cleveland Clinic
Coriell Institute
Cryo Bio System
Cryoport Systems
CRYOTHERM
Cureline
Custom BioGenic Systems
Duke University and Duke University Health System
Greiner Bio-One International GmbH
Kaiser Permanente
Mayo Clinic
Northwestern University
Personalized Stem Cells
Precision Stability Storage
REPROCELL
Rhode Island Biobank (Brown University)
RUSH University
Sampled
SCISAFE
SPT Labtech
Stanford University
Tecan Trading AG
The Johns Hopkins University
The University of Arizona
The University of Chicago Medical Center
The University of Iowa
The University of Pennsylvania
The University of Texas MD Anderson Cancer Center
Thermo Fisher Scientific
Thermogenesis Holdings
University of South Alabama
Washington University
WiCell
Yale School of Medicine

KEY QUESTIONS ANSWERED:

1. Which sample type dominates the U.S. cryogenic biobanking services market share?

2. How big is the U.S. cryogenic biobanking services market?

3. What is the growth rate of the U.S. cryogenic biobanking services market?

4. What are the significant trends in the U.S. cryogenic biobanking services market?

Product Code: ARZ250112

1. SCOPE & COVERAGE

1.1. MARKET DEFINITION
- 1.1.1. INCLUSIONS
- 1.1.2. EXCLUSIONS
- 1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET SEGMENTATION COVERAGE & DEFINITIONS
- 1.2.1. MARKET BY SERVICE TYPE
- 1.2.2. MARKET BY SAMPLE TYPE
- 1.2.3. MARKET BY APPLICATION
- 1.2.4. MARKET BY OWNERSHIP
- 1.2.5. MARKET BY END-USER
- 1.2.6. COUNTRIES COVERED
1.3. MARKET DERIVATION
- 1.3.1. BASE YEAR

2. PREMIUM INSIGHTS

2.1. OPPORTUNITY POCKETS
2.2. OVERVIEW

3. MARKET AT A GLANCE

4. INTRODUCTION

4.1. OVERVIEW

5. MARKET OPPORTUNITIES & TRENDS

5.1. GROWING CONSERVATION OF CORD BLOOD STEM CELLS OF NEWBORNS
5.2. EXPANSION OF VIRTUAL BIOBANKING
5.3. ADVANCES IN CRYOPRESERVATION TECHNOLOGY
5.4. EMERGENCE OF PERSONALIZED BIOBANKING

6. MARKET GROWTH ENABLERS

6.1. RISING PREVALENCE OF CHRONIC DISEASES
6.2. SURGE IN CLINICAL TRIALS FOR NEW DRUGS AND THERAPIES
6.3. EXPANSION OF GENOMICS AND PROTEOMICS RESEARCH
6.4. FAVORABLE GOVERNMENT AND PRIVATE FUNDING

7. MARKET RESTRAINTS

7.1. HIGH OPERATIONAL COSTS
7.2. ETHICAL CONCERNS AND CONSENT MANAGEMENT
7.3. SAMPLE QUALITY AND VIABILITY RISKS

8. MARKET LANDSCAPE

8.1. MARKET OVERVIEW
8.2. MARKET SIZE & FORECAST
8.3. FIVE FORCES ANALYSIS
- 8.3.1. THREAT OF NEW ENTRANTS
- 8.3.2. BARGAINING POWER OF SUPPLIERS
- 8.3.3. BARGAINING POWER OF BUYERS
- 8.3.4. THREAT OF SUBSTITUTES
- 8.3.5. COMPETITIVE RIVALRY

9. SERVICE TYPE

9.1. MARKET SNAPSHOT & GROWTH ENGINE
9.2. MARKET OVERVIEW
9.3. BIOBANKING & REPOSITORY
- 9.3.1. MARKET OVERVIEW
- 9.3.2. MARKET SIZE & FORECAST
9.4. VALIDATION/QUALIFICATION
- 9.4.1. MARKET OVERVIEW
- 9.4.2. MARKET SIZE & FORECAST
9.5. LAB PROCESSING
- 9.5.1. MARKET OVERVIEW
- 9.5.2. MARKET SIZE & FORECAST
9.6. OTHERS
- 9.6.1. MARKET OVERVIEW
- 9.6.2. MARKET SIZE & FORECAST

10. SAMPLE TYPE

10.1. MARKET SNAPSHOT & GROWTH ENGINE
10.2. MARKET OVERVIEW
10.3. HUMAN SAMPLES
- 10.3.1. MARKET OVERVIEW
- 10.3.2. MARKET SIZE & FORECAST
10.4. ANIMAL SAMPLES
- 10.4.1. MARKET OVERVIEW
- 10.4.2. MARKET SIZE & FORECAST
10.5. PLANT SAMPLES
- 10.5.1. MARKET OVERVIEW
- 10.5.2. MARKET SIZE & FORECAST
10.6. OTHERS
- 10.6.1. MARKET OVERVIEW
- 10.6.2. MARKET SIZE & FORECAST

11. APPLICATION

11.1. MARKET SNAPSHOT & GROWTH ENGINE
11.2. MARKET OVERVIEW
11.3. DRUG DISCOVERY & DEVELOPMENT
- 11.3.1. MARKET OVERVIEW
- 11.3.2. MARKET SIZE & FORECAST
11.4. REGENERATIVE MEDICINE
- 11.4.1. MARKET OVERVIEW
- 11.4.2. MARKET SIZE & FORECAST
11.5. EPIDEMIOLOGY & POPULATION HEALTH
- 11.5.1. MARKET OVERVIEW
- 11.5.2. MARKET SIZE & FORECAST
11.6. CONSERVATION & ECOSYSTEM RESTORATION
- 11.6.1. MARKET OVERVIEW
- 11.6.2. MARKET SIZE & FORECAST

12. OWNERSHIP

12.1. MARKET SNAPSHOT & GROWTH ENGINE
12.2. MARKET OVERVIEW
12.3. UNIVERSITIES
- 12.3.1. MARKET OVERVIEW
- 12.3.2. MARKET SIZE & FORECAST
12.4. NON-PROFIT ORGANIZATIONS
- 12.4.1. MARKET OVERVIEW
- 12.4.2. MARKET SIZE & FORECAST
12.5. STATE/GOVERNMENT AGENCIES
- 12.5.1. MARKET OVERVIEW
- 12.5.2. MARKET SIZE & FORECAST
12.6. PRIVATE ORGANIZATIONS
- 12.6.1. MARKET OVERVIEW
- 12.6.2. MARKET SIZE & FORECAST

13. END-USERS

13.1. MARKET SNAPSHOT & GROWTH ENGINE
13.2. MARKET OVERVIEW
13.3. PHARMA & BIOTECH COMPANIES
- 13.3.1. MARKET OVERVIEW
- 13.3.2. MARKET SIZE & FORECAST
13.4. ACADEMIC & RESEARCH INSTITUTES
- 13.4.1. MARKET OVERVIEW
- 13.4.2. MARKET SIZE & FORECAST
13.5. HEALTHCARE PROVIDERS
- 13.5.1. MARKET OVERVIEW
- 13.5.2. MARKET SIZE & FORECAST
13.6. CROS AND CDMOS
- 13.6.1. MARKET OVERVIEW
- 13.6.2. MARKET SIZE & FORECAST
13.7. LIFE SCIENCES COMPANIES
- 13.7.1. MARKET OVERVIEW
- 13.7.2. MARKET SIZE & FORECAST
13.8. OTHERS
- 13.8.1. MARKET OVERVIEW
- 13.8.2. MARKET SIZE & FORECAST

14. COMPETITIVE LANDSCAPE

14.1. COMPETITION OVERVIEW

15. COMPANY PROFILES

15.1. AZENTA LIFE SCIENCES
- 15.1.1. BUSINESS OVERVIEW
- 15.1.2. SERVICE OFFERINGS
15.2. BIODOCK (FUTURE HEALTH GROUP)
- 15.2.1. BUSINESS OVERVIEW
- 15.2.2. SERVICE OFFERINGS
15.3. BIOKRYO
- 15.3.1. BUSINESS OVERVIEW
- 15.3.2. SERVICE OFFERINGS
15.4. BIOREPOSITORY RESOURCES (TOBIN SCIENTIFIC)
- 15.4.1. BUSINESS OVERVIEW
- 15.4.2. SERVICE OFFERINGS
15.5. BIOSTORAGE
- 15.5.1. BUSINESS OVERVIEW
- 15.5.2. SERVICE OFFERINGS
15.6. BOCABIO
- 15.6.1. BUSINESS OVERVIEW
- 15.6.2. SERVICE OFFERINGS
15.7. BRIGHAM AND WOMEN'S HOSPITAL DIVISION OF PREVENTIVE MEDICINE
- 15.7.1. BUSINESS OVERVIEW
- 15.7.2. SERVICE OFFERINGS
15.8. CELL CULTURE COMPANY
- 15.8.1. BUSINESS OVERVIEW
- 15.8.2. SERVICE OFFERINGS
15.9. CLEVELAND CLINIC
- 15.9.1. BUSINESS OVERVIEW
- 15.9.2. SERVICE OFFERINGS
15.10. CORIELL INSTITUTE
- 15.10.1. BUSINESS OVERVIEW
- 15.10.2. SERVICE OFFERINGS
15.11. CRYO BIOSYSTEM
- 15.11.1. BUSINESS OVERVIEW
- 15.11.2. SERVICE OFFERINGS
15.12. CRYOPORT SYSTEMS
- 15.12.1. BUSINESS OVERVIEW
- 15.12.2. SERVICE OFFERINGS
15.13. CRYOTHERM
- 15.13.1. BUSINESS OVERVIEW
- 15.13.2. SERVICE OFFERINGS
15.14. CURELINE
- 15.14.1. BUSINESS OVERVIEW
- 15.14.2. SERVICE OFFERINGS
15.15. CUSTOM BIOGENIC SYSTEMS
- 15.15.1. BUSINESS OVERVIEW
- 15.15.2. SERVICE OFFERINGS
15.16. DUKE UNIVERSITY AND DUKE UNIVERSITY HEALTH SYSTEM
- 15.16.1. BUSINESS OVERVIEW
- 15.16.2. SERVICE OFFERINGS
15.17. GREINER BIO-ONE INTERNATIONAL GMBH
- 15.17.1. BUSINESS OVERVIEW
- 15.17.2. SERVICE OFFERINGS
15.18. KAISER PERMANENTE
- 15.18.1. BUSINESS OVERVIEW
- 15.18.2. SERVICE OFFERINGS
15.19. MAYO CLINIC
- 15.19.1. BUSINESS OVERVIEW
- 15.19.2. SERVICE OFFERINGS
15.20. NORTHWESTERN UNIVERSITY
- 15.20.1. BUSINESS OVERVIEW
- 15.20.2. SERVICE OFFERINGS
15.21. PERSONALIZED STEM CELLS
- 15.21.1. BUSINESS OVERVIEW
- 15.21.2. SERVICE OFFERINGS
15.22. PRECISION STABILITY STORAGE
- 15.22.1. BUSINESS OVERVIEW
- 15.22.2. SERVICE OFFERINGS
15.23. REPROCELL
- 15.23.1. BUSINESS OVERVIEW
- 15.23.2. SERVICE OFFERINGS
15.24. RHODE ISLAND BIOBANK (BROWN UNIVERSITY)
- 15.24.1. BUSINESS OVERVIEW
- 15.24.2. SERVICE OFFERINGS
15.25. RUSH UNIVERSITY
- 15.25.1. BUSINESS OVERVIEW
- 15.25.2. SERVICE OFFERINGS
15.26. SAMPLED
- 15.26.1. BUSINESS OVERVIEW
- 15.26.2. SERVICE OFFERINGS
15.27. SCISAFE
- 15.27.1. BUSINESS OVERVIEW
- 15.27.2. SERVICE OFFERINGS
15.28. SPT LABTECH
- 15.28.1. BUSINESS OVERVIEW
- 15.28.2. SERVICE OFFERINGS
15.29. STANFORD UNIVERSITY
- 15.29.1. BUSINESS OVERVIEW
- 15.29.2. SERVICE OFFERINGS
15.30. TECAN TRADING AG
- 15.30.1. BUSINESS OVERVIEW
- 15.30.2. SERVICE OFFERINGS
15.31. THE JOHNS HOPKINS UNIVERSITY
- 15.31.1. BUSINESS OVERVIEW
- 15.31.2. SERVICE OFFERINGS
15.32. THE UNIVERSITY OF ARIZONA
- 15.32.1. BUSINESS OVERVIEW
- 15.32.2. SERVICE OFFERINGS
15.33. THE UNIVERSITY OF CHICAGO MEDICAL CENTER
- 15.33.1. BUSINESS OVERVIEW
- 15.33.2. SERVICE OFFERINGS
15.34. THE UNIVERSITY OF IOWA
- 15.34.1. BUSINESS OVERVIEW
- 15.34.2. SERVICE OFFERINGS
15.35. THE UNIVERSITY OF PENNSYLVANIA
- 15.35.1. BUSINESS OVERVIEW
- 15.35.2. SERVICE OFFERINGS
15.36. THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
- 15.36.1. BUSINESS OVERVIEW
- 15.36.2. SERVICE OFFERINGS
15.37. THERMO FISHER SCIENTIFIC
- 15.37.1. BUSINESS OVERVIEW
- 15.37.2. SERVICE OFFERINGS
15.38. THERMOGENESIS HOLDINGS
- 15.38.1. BUSINESS OVERVIEW
- 15.38.2. SERVICE OFFERINGS
15.39. UNIVERSITY OF SOUTH ALABAMA
- 15.39.1. BUSINESS OVERVIEW
- 15.39.2. SERVICE OFFERINGS
15.40. WASHINGTON UNIVERSITY
- 15.40.1. BUSINESS OVERVIEW
- 15.40.2. SERVICE OFFERINGS
15.41. WICELL
- 15.41.1. BUSINESS OVERVIEW
- 15.41.2. SERVICE OFFERINGS
15.42. YALE SCHOOL OF MEDICINE
- 15.42.1. BUSINESS OVERVIEW
- 15.42.2. SERVICE OFFERINGS

16. REPORT SUMMARY

16.1. KEY TAKEAWAYS
16.2. STRATEGIC RECOMMENDATIONS

17. QUANTITATIVE SUMMARY

17.1. MARKET BY SERVICE TYPE
17.2. MARKET BY SAMPLE TYPE
17.3. MARKET BY APPLICATION
17.4. MARKET BY OWNERSHIP
17.5. MARKET BY END-USER

18. APPENDIX

18.1. RESEARCH METHODOLOGY
18.2. RESEARCH PROCESS
18.3. REPORT ASSUMPTIONS & CAVEATS
- 18.3.1. KEY CAVEATS
- 18.3.2. CURRENCY CONVERSION
18.4. ABBREVIATIONS